Search Results for: Fixed waxes
fixed combination eye drop of ripasudil hydrochloride hydrate, a rho kinase inhibitor, and brimonidine tartrate started phase clinical studies in japan [developmental code: k- ] february , dear all kowa company, ltd. kowa company, ltd.
(headquarters: nagoya, japan, president & ceo: yoshihiro miwa, hereafter referred to as "kowa") announced that phase clinical studies of fixed combination eye drop "ripasudil hydrochloride hydrate" (hereafter referred to as "ripasudil"), a rho kinase inhibitor, and brimonidine tartrate (developmental...
https://www.kowa.co.jp/eng/news/press20021902.pdf